Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$3.95

0.35 (9.72%)

07:11
10/12/18
10/12
07:11
10/12/18
07:11

AcelRx stock trading halted; FDA Advisory committee to review DSUVIA NDA

AcelRx Pharmaceuticals announced that NASDAQ has halted trading of the company's common stock. The U.S. FDA Anesthetic and Analgesic Drug Products Advisory Committee is meeting today to review AcelRx's New Drug Application for DSUVIA, a 30 mcg sufentanil sublingual tablet for the management of moderate-to-severe acute pain in adult patients in a medically supervised setting. The Advisory Committee meeting is scheduled from 8:00 a.m. to 5:00 p.m. ET. The briefing materials can be found on the FDA website. The Prescription Drug User Fee Act date for completion of the review of the company's NDA for DSUVIA is November 3, 2018.

  • 12

    Oct

  • 03

    Nov

ACRX AcelRx
$3.95

0.35 (9.72%)

10/10/18
CANT
10/10/18
NO CHANGE
Target $6
CANT
Overweight
Positive vote on AcelRx's Dsuvia 'a real possibility,' says Cantor Fitzgerald
After the FDA released the briefing documents for this Friday's Advisory Committee meeting to review AcelRx's Dsuvia, Cantor Fitzgerald analyst Brandon Folkes said he expects "a robust discussion" and believes a positive vote on Dsuvia being used only in a medically supervised setting "is a real possibility." He attributes the initial negative reaction in the stock to extracts from the 2017 CRL, which was attached as an appendix, but he believes AcelRx has addressed these concerns and views the briefing documents as an incremental positive. Folkes keeps an Overweight rating and $6 price target on AcelRx shares.
10/10/18
LTCO
10/10/18
NO CHANGE
Target $10
LTCO
Buy
AcelRx price target raised to $10 from $7 at Ladenburg
10/10/18
LTCO
10/10/18
NO CHANGE
Target $10
LTCO
Buy
Ladenburg says briefing docs support Dsuvia approval, ups AcelRx target to $10
After the FDA released briefing documents ahead of Friday's Advisory Committee meeting for AcelRx, Ladenburg analyst Michael Higgins said the documents "could not be more supportive of Dsuvia." He believes pre-market weakness in the shares occurred as investors initially read the comments from the prior review, which had produced a CRL, but the documents are actually "very positive on Dsuvia," he contends. Higgins, who expects the committee to vote in support of Dsuvia's efficacy, safety, proposed REMS and overall approval, raised his price target on AcelRx shares to $10 from $7 and keeps a Buy rating on the shares.
10/10/18
HCWC
10/10/18
NO CHANGE
Target $7
HCWC
Buy
AcelRx briefing docs bode well for positive panel, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce believes the briefing document released this morning for the October 12 FDA meeting to review the resubmitted new drug application of Dsuvia bode well for a positive panel vote. The statements and tone of the FDA reviewers are broadly supportive of approval, Arce tells investors in a research note. The analyst affirms a Buy rating on AcelRx Pharmaceuticals with a $7 price target.

TODAY'S FREE FLY STORIES

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

BSX

Boston Scientific

$40.03

-0.1 (-0.25%)

10:30
02/21/19
02/21
10:30
02/21/19
10:30
Options
Bullish option flow in Boston Scientific »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

SNPS

Synopsys

$100.68

-2.3 (-2.23%)

10:26
02/21/19
02/21
10:26
02/21/19
10:26
Recommendations
Synopsys analyst commentary  »

Synopsys weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 03

    Mar

  • 08

    Mar

  • 14

    Mar

  • 17

    Mar

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

NWL

Newell Brands

$17.18

0.05 (0.29%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Periodicals
Newell Brands CEO faces board pressure following poor sales, WSJ reports »

Newell Brands CEO Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley consumer goods analysts to hold analyst/industry conference call »

Executive Director of…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

, ESALY

Eisai

$0.00

(0.00%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan large-cap biotech analysts to hold an analyst/industry conference call »

Large Cap Biotech Analyst…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan retail analysts to hold an analyst/industry conference call »

Retail Analysts Boss and…

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

EEM

iShares MSCI Emerging Markets ETF

$42.48

-0.175 (-0.41%)

10:20
02/21/19
02/21
10:20
02/21/19
10:20
Options
Size three-way spread in iShares Emerging Markets Fund as shares tick lower »

Size three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/21/19
02/21
10:17
02/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/21/19
02/21
10:16
02/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
U.S. leading index dipped 0.1% to 111.3 in January »

U.S. leading index dipped…

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
Breaking General news story  »

Week of 2/15 EIA Natural…

HOME

At Home Group

$23.84

0.01 (0.04%)

, HLIT

Harmonic

$5.51

0.19 (3.57%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

HOME

At Home Group

$23.84

0.01 (0.04%)

HLIT

Harmonic

$5.51

0.19 (3.57%)

ATKR

Atkore

$24.08

-0.09 (-0.37%)

BTX

BioTime

$1.24

0.08 (6.90%)

VRCA

Verrica Pharmaceuticals

$10.99

(0.00%)

APHA

Aphria

$10.40

0.24 (2.36%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$6.11

0.13 (2.17%)

CGC

Canopy Growth

$45.44

-0.74 (-1.60%)

ACB

Aurora Cannabis

$7.18

0.12 (1.70%)

TLRY

Tilray

$80.25

-0.82 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

  • 18

    Mar

GRMN

Garmin

$82.02

-1 (-1.20%)

, BIIB

Biogen

$324.13

-10.88 (-3.25%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GRMN

Garmin

$82.02

-1 (-1.20%)

BIIB

Biogen

$324.13

-10.88 (-3.25%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

DHI

D.R. Horton

$39.91

0.04 (0.10%)

LEN

Lennar

$49.12

0.16 (0.33%)

GIS

General Mills

$46.68

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

CAJ

Canon

$29.10

-0.02 (-0.07%)

, SAM

Boston Beer

$302.00

34.05 (12.71%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

CAJ

Canon

$29.10

-0.02 (-0.07%)

SAM

Boston Beer

$302.00

34.05 (12.71%)

X

U.S. Steel

$24.25

0.25 (1.04%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

AAN

Aaron's

$54.10

0.46 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$18.86

-0.57 (-2.93%)

10:10
02/21/19
02/21
10:10
02/21/19
10:10
Options
Put buyers in Kemet Corp as shares slip »

Put buyers in Kemet Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
02/21/19
02/21
10:10
02/21/19
10:10
General news
U.S. existing home sales dropped 1.2% in January to 4.94 M »

U.S. existing home sales…

CPRX

Catalyst Pharmaceuticals

$2.80

0.04 (1.45%)

10:08
02/21/19
02/21
10:08
02/21/19
10:08
On The Fly
Catalyst Pharmaceuticals defends pricing for Firdapse after Sanders slams company »

Nearly three weeks after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
Leading Indicators data reported »

January Leading…

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
FX Action: The dollar »

FX Action: The dollar was…

10:03
02/21/19
02/21
10:03
02/21/19
10:03
General news
Existing Home Sales data reported »

January Existing Home…

APYX

Apyx Medical

$8.36

-0.16 (-1.88%)

10:02
02/21/19
02/21
10:02
02/21/19
10:02
Hot Stocks
Apyx Medical mentioned cautiously in a Seeking Alpha article 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 13

    Mar

  • 21

    Mar

ICLR

Icon

$140.52

-5.09 (-3.50%)

10:01
02/21/19
02/21
10:01
02/21/19
10:01
Hot Stocks
Icon acquires MolecularMD, terms not disclosed »

MolecularMD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

EVTC

Evertec

$27.23

-3.42 (-11.16%)

10:00
02/21/19
02/21
10:00
02/21/19
10:00
Hot Stocks
Evertec falls -10.9% »

Evertec is down -10.9%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.